Abstract:

Human epidermal growth factor receptor 2( HER2) positive salivary ductal carcinoma (SDC) is relatively rare in clinical practice. This article reports one patient, who had progressed after adjuvant therapy received HER2-targeted drug therapy, and the effect of HER2-targeted drug treatment was significant. The efficacy of HER2 targeted therapy combined with chemotherapy in the treatment of HER2-positive SDC may be more advantageous than traditional chemotherapy, but large-scale controlled studies are still needed.

Key words: salivary ductal carcinoma (SDC), human epidermal growth factor receptor 2 (HER2）, targeted therapy

摘要：

人表皮生长因子受体2（human epidermal growth factor receptor 2，HER2）阳性涎腺导管癌（salivary ductal carcinoma，SDC）在临床上较少见。本文报道1例该病术后经辅助治疗后病情进展的患者，行HER2靶向药物治疗，效果显著。应用HER2靶向药物联合化疗治疗HER2阳性SDC的疗效可能较传统化疗法更具优势，但仍有待于大样本对照研究。

关键词: 涎腺导管癌, 人表皮生长因子受体2, 靶向治疗

CLC Number: 

• R782